bluuebunny/crossref_metadata_2025_split huggingface dataset:
QUALITY OF TREATMENT OF ARTERIAL HYPERTENSION IN COMBATANTS TAKING INTO ACCOUNT THE PRESENT COMORBID PATHOLOGY
Authors: Seliuk Olha , Voronko Andrii , Buzhenko Alla , Seliuk Mariana , Kozachok Mykola , Dmytruk Liliia , Buzhenko Ivan , Havretskyi Anatolii , Voronko Oleksii , Buzhenko Zhanna 
Published: June 2023

Objective:
Assessment of compliance of treatment of arterial hypertension (AH) in participants of modern armed conflicts with the requirements of evidence-based medicine, taking into account their comorbid pathology.

Design and method:
The design of the study was passive retrospective one-time (cross-sectional). The medical charts of inpatient patients of 213 male combatants, aged 27-59 years, average age 45.0 ± 6.8 years, who underwent treatment during 2018-2021, were analyzed by the method of random sampling.

Results:
It was established that all combatants with hypertension were prescribed antihypertensive drugs: angiotensin-converting enzyme inhibitors (54% of patients), calcium channel blockers (26%), angiotensin receptor blockers (25%) (that is, not all patients used angiotensin-converting enzyme inhibitors or angiotensin receptor blockers), beta blockers (24%) and diuretics (16%). In combatants suffering from hypertension with comorbid coronary heart disease (CHD), beta blockers were prescribed in 26%, calcium channel blockers in 28%, statins in only 45% of patients, without monitoring the achievement of target levels of low-density lipoprotein cholesterol density; antiplatelet therapy was prescribed for 70% of patients, which does not meet the requirements of modern medical and technological documents and needs correction. An insufficient prescription of antihypertensive drugs from the groups of beta blockers (26% of patients) and calcium channel blockers (28%) was established in military personnel with hypertension - participants in modern armed conflicts with comorbid coronary artery disease. Inadequate prescribing of statins (only in 45% of patients) and antiplatelet therapy (70%) to patients with hypertension with comorbid coronary heart disease and lack of strict control of low-density lipoprotein cholesterol levels were revealed.

Conclusions:
It is necessary to increase the awareness of military doctors about the need for cardiovascular risk stratification in all patients with hypertension and patients with hypertension with comorbid coronary heart disease of combatants, regarding modern requirements for the treatment of patients with hypertension with concomitant pathology, on issues of safety and feasibility of prescribing statins and antiplatelet therapy to combatants with hypertension and concomitant coronary heart disease to reduce the risk of developing cardiovascular complications and improve the prognosis with this comorbidity.
ASSOCIATION BETWEEN BRACHIAL-ANKLE PULSE WAVE VELOCITY AND LONG-TERM OUTCOMES FOLLOWING PERCUTANEOUS CORONARY INTERVENTION
Authors: Shin Jeong-Hun , Kim Byung Sik , Hwang Jin-Yong , Jeong Young-Hoon 
Published: June 2023

Objective:
The aim of this study was to determine the associations between brachial-ankle pulse wave velocity (baPWV), a measure of arterial stiffness, and risk of long-term clinical outcomes in patients who underwent percutaneous coronary intervention (PCI).

Design and method:
A prospective single-center registry was used to identify 3930 patients with baseline baPWV measurements who underwent PCI between 2014 and 2018. Major adverse cardiac and cerebrovascular event (MACCE, a composite of all-cause death, spontaneous myocardial infarction, and non-fatal stroke) and net adverse clinical event (NACE, a composite of MACCE components and major bleeding) were evaluated up to 4 years.

Results:
From the registry, 980 (24.9%) patients had high baPWV (>1850 cm/s) and 2,950 (75.1%) patients had low baPWV (< = 1850 cm/s). During follow-up period of up to 4 years, MACCE occurred in 266 (6.8%) patients (112 (11.4%) in high baPWV and 154 (5.2%) in low baPWV) and NACE occurred in 309 (7.9%) patients (131(13.4%) in high baPWV and 178 (6.0%) in low baPWV). In multivariable analysis, patients with high baPWV showed a higher risk of occurring MACCE (adjusted hazard ratio [HR] 1.441; 95% confidence interval [CI], 1.101–1.886) and NACE (adjusted HR 1.505; 95% CI, 1.174–1.929) than those with low baPWV. In addition, predictive performance was significantly increased when PWV was incorporated into the Cox regression models for MACCE (net reclassification improvement [NRI] 0.154, p = 0.040; integrated discrimination improvement [IDI] 0.003, p = 0.013) and NACE (NRI 0.144, p = 0.027; IDI 0.003, p = 0.027).

Conclusions:
Elevated baPWV in patients who underwent PCI, is significantly associated with the long-term clinical outcomes and may be valuable for the initial assessment to identify high-risk patients following PCI.
POTENTIAL FUNCTIONAL ASSOCIATION OF MIR-21 AND MIR-133B WITH ATHEROSCLEROTIC CORONARY ARTERY DISEASE THROUGH MODULATING THEIR NOVEL TARGET GENES SGPP1, ATG5, AND LRP6
Authors: Kumar Dinesh , Narang Rajiv , Saluja Daman , Srivastava Kamna 
Published: June 2023

Objective:
Atherosclerosis, a progressive manifestation of coronary artery disease (CAD), is an inflammatory disorder characterised by the accumulation of atherosclerotic plaque. MicroRNAs regulate several pathophysiological events of atherosclerosis. In our previous study, miR-133b and miR-21 were reported to be differentially expressed in CAD patients as compared to controls, suggesting their possible implications in the pathophysiology of CAD. To better understand their functional role we sought to predict their target genes through bioinformatic tools and validate them while assessing their expression at the protein level in CAD subjects as well as in THP1 macrophages treated with respective miRNA inhibitors.

Design and method:
Upon bioinformatics approach, three predicted target genes, SGPP1, ATG5 and LRP6, were chosen from 22 predicted target genes of candidate miRNAs, which have not been explored so far for their association with the respective miRNAs in CAD or related pathologies. Validation of the expressions was performed through western blot analysis.

Results:
Following the prediction of target genes and validation through immunoblotting, SGPP1 was observed to be a potential target gene of miR-133b, ATG5 of miR-21 and LRP6 of both miR-133b and miR-21. SGPP1 was identified to be upregulated in CAD patients whereas ATG5 and LRP6 were both observed to be downregulated in CAD patients as compared to controls. Moreover, the protein expression pattern of all the target genes was observed to be modulated, when cells were treated with respective miRNAs inhibitors.

Conclusions:
The results from the present study suggest that SGPP1, ATG5 and LRP6 are potential target genes that may serve as possible therapeutic targets in the management of CAD which undoubtedly merit further experimental confirmation.
IMPACT OF CARDIOVASCULAR RISK AND HYPERTENSION ON SUBCLINICAL CORONARY ATHEROSCLEROSIS IN ASYMPTOMATIC DIABETIC INDIVIDUALS
Authors: Jeon Young Hun , Park Gyung-Min 
Published: June 2023

Objective:
This study sought to evaluate the effect of 10-year ASCVD (Atherosclerotic Cardiovascular Disease) risk and blood pressure (BP) on subclinical coronary atherosclerosis in asymptomatic diabetic individuals.

Design and method:
We analyzed 739 asymptomatic diabetic individuals (mean age 55.5 ± 7.3 years; 541 [73.2%] men) with no prior history of coronary artery disease who voluntarily underwent coronary computed tomography angiography (CCTA) as part of a general health examination. The classification of BP was adapted from the American College of Cardiology/American Heart Association 2017 guideline. Study participants were categorized as low (<15%) and high ASCVD risk (> = 15%) groups, respectively. Subclinical coronary atherosclerosis was defined as the presence of any coronary plaque by CCTA.

Results:
In subjects with low ASCVD risk (n = 498), after adjustment for cardiovascular risk factors, subclinical coronary atherosclerosis was not associated with elevated BP, stage 1, and stage 2 hypertension groups compared with normal BP group (P for all > 0.05). On the other hand, in subjects with high ASCVD risk (n = 241), there was no statistically difference in the adjusted odds ratios of both elevated BP (adjusted odds ratio [aOR] 2.068; 95% confidence interval [CI], 0.703–6.080; P = 0.187) and stage 1 hypertension groups (aOR, 1.533; 95% CI, 0.679–3.459; P = 0.304) for the presence of any coronary plaque. However, the stage 2 hypertension group had a significant association with subclinical coronary atherosclerosis (aOR, 4.127; 95% CI, 1.592–10.696; P = 0.004).

Conclusions:
In asymptomatic diabetic individuals with low ASCVD risk, BP levels were not associated with an increased risk of subclinical coronary atherosclerosis. However, in those with high ASCVD risk, stage 2 hypertension was only associated with an increased risk of subclinical coronary atherosclerosis. These results suggest that hypertension management may be different in diabetic individuals according to the their ASCVD risk.
WHEN PERCUTANEOUS CORONARY INTERVENTION (PCI) IS NOT AN OPTION - CONSERVATIVE TREATMENT OF STEMI DUE TO THE CONTRAINDICATIONS AND SEVERE COVID-19 INFECTION
Authors: Zbroch Edyta , Adasko Grzegorz , Cabaj Marta , Barano Magdalena , Zbroch Aleksandra , Wawiernia Julia , Zalewska Aleksandra , Zapora-Kurel Agnieszka 
Published: June 2023

Objective:
The case report presents patient with the history of ST-segment elevation myocardial infarction (STEMI) and COVID-19 infection. STEMI is one of the acute coronary syndromes, defined as sudden ischaemia of the heart muscle. The most common cause of STEMI is the abrupt cessation in coronary artery blood flow based on pre-existing atherosclerosis. Percutaneous coronary intervention (PCI) remains the gold standard for patients with STEMI. In some cases, due to contraindications, only conservative treatment is possible.

Design and method:
Case report presentation of the patient admitted to the hospital due to the shortness of breath, cough and chest pain as well as analysis of symptoms, additional tests, diagnosis and treatment options.

Results:
A 78-year-old woman with the history of heart failure, type 2 diabetes mellitus, obesity, hypertension, chronic kidney disease, several myocardial infarctions, anaemia and thrombocytopenia in the course of myelodysplastic syndrome was admitted to Department of Internal Medicine and Hypertension because of compressive chest pain, deteriorating shortness of breath and cough. In the Emergency Unit COVID-19 infection was confirmed, as well as STEMI was diagnosed. An invasive cardiologist, due to severe thrombocytopenia, qualified the patient for conservative treatment, including fondaparinux, statin, nitroglycerin infusion and beta blocker. Due to the severe course of COVID-19 infection oxygen therapy and pharmacotherapy were implemented. During hospitalization, an attack of atrial fibrillation occurred. Considering the risk of haemorrhage an apixaban was recommended, without antiplatelet agent. The patient was discharged home in general good condition.

Conclusions:
Reperfusion treatment involves PCI, which should be performed within 120 minutes from the diagnosis of STEMI. Other methods include coronary artery bypass grafting and fibrinolytic treatment. Due to the increased risk of complications, particularly the high bleeding risk, conservative treatment was applied, resulting in a significant improvement of the patient's condition, despite unexpected new incidents.
HEART FAILURE PATIENT AND MEDICAL WORKERS, INTERACTION POST DISCHARGE: SINGLE CENTER STUDY
Authors: Gasimov Zaur , Dadashova Gulnaz , Javadova Tarana , Aliyeva Sevinj 
Published: June 2023

Objective:
It is well known that the period after discharge from the hospital is very important for a patient with heart failure. For to achieve the desired result, improve the quality of life, reduce the number of repeated hospitalizations, increase life expectancy, it is necessary to coordinate all parts of the healthcare system.
The purpose of the study: to find out the level of involvement of medical workers of various parts of the health care system in the treatment of patients with heart failure.

Design and method:
91 patient, 61male, 30 women,mean age 59, years, 31-84, mean hospitalization rate mean 4 times, 1-10+, represented, 33,7%, sample of 271 patients with heart failure hospitalized at Research Institute of Cardiology, Baku, Azerbaijan in 11 june-18 august 2022 represented study population. Patient-hospital-ambulatory interaction related questionnaire,15questions, table 1, and Voils patient adherence to medications questionnaire, 3main+18 detailed question, were used.

Results:
74,7% noticed that after discharge they being in touch with hospital cardiologist,73,4% being in touch no later than 1 time in a 3 month,mainly once a month, 54% of patients recognized hospital cardiologist as –my doctor,44% offered to the hospital cardiologist during post-discharge period this percentage increase to 52%patients when their condition worsens. Only 23% of patients offered to polyclinic in the period after discharge, drive by patients with heart failure and Type 2 Diabetes. 12% of patients noticed that they offer to the hospital cardiologist and polyclinic doctor.73% noticed that have no contacts with polyclinic medical workers, neither cardiologist or general practice. 79% of patients noticed high adherence to medication. Cardiologists weak adherence related to the list and dosages of medications recommended in modern guidelines has been observed. table 2.

Conclusions:
It is necessary to organize optimal medical care for the heart failure patients and to work measures for effective interaction of all chains of medical system.
COVID-19 INFECTION IN PATIENTS WITH PROVEN HEART DISEASE
Authors: Ouankou Christian Ngongang , Njonnou Sylvain Raoul Simeni , Kuate Liliane Mfeukeu , Ndedi Claudine Jessica Yondo , Chemgne Marie Ida , Lekpa Fernando Kemta , Ouankou Merimee , Choukem Simeon Pierre 
Published: June 2023

Objective:
The COVID-19 pandemic remains a hot topic whose results are highly uncertain. This acute respiratory infection is mainly transmitted through respiratory droplets and contact routes. Frail patients such as those with severe heart disease are at higher risk of contracting moderate to severe forms of COVID-19 pneumonia. our goal was to determine the prevalence of COVID-19 in patients with proven heart failure and to give the result of this disease.

Design and method:
We collected data from the medical records of heart failure patients followed at the Medical and Cardiology Center over the past two years and looked for the onset of COVID-19 disease, risk factors for poor outcomes as well as the final outcome of the disease.

Results:
Out of 130 medical records, we recorded a total of 66 cases. The mean age of patients was 61.4 ± 17.8 years. The sex ratio was 0.81. LV systolic function was preserved in 47.7% of cases. COVID-19-related pneumonia was detected in 14.9% of cases; The clinical presentation was dominated by respiratory distress associated with moderate oxygen desaturation and fever. Forty-six patients (70.7%) were on renin-angiotensin-aldosterone inhibitors. Poor outcome factors were: BT systolic dysfunction (52.3%), atrial fibrillation (31.3%), pulmonary arterial hypertension (16.4%), impaired renal function (41.8%), impaired liver function (59.7%), and at least 10-fold increase in NT-Pro-BNP values (55.2%). In addition, LVH was observed in 32.8% of cases, complete LBBB in 13.4% of cases, and significant LV dilation in 55.2% of cases. There have been 8 deaths, including 5 related to COVID-19-related pneumonia. Survivors received long-term chest physiotherapy in addition to treatment for heart failure.

Conclusions:
Acute pneumonia due to COVID-19 can have a negative impact on the prognosis of heart disease. Thus, the factors of poor performance should encourage the isolation and/or treatment of these at-risk populations.
WHAT HAPPENED IN THE CARDIOLOGICAL OUTPATIENT PRACTICE AFTER THE COVID-19 PANDEMIA?
Authors: Gruev Ivan , Tsanova Veska 
Published: June 2023

Objective:
The COVID 19 pandemia has passed its peak, but the consequences are still present and unclear. COVID 19 infection is a respiratory, but also a vascular disease and future will show the real impact on the cardiovascular health.

Design and method:
We studied the medical records of the patients in one outpatient cardiological practice in Sofia, Bulgaria.
We found out that the patients had returned to the clinical visits in the practice. They did not postpone their appointments anymore.
During last year, 712 clinical examinations were performed in this particular practice. 70 % of the patients had passed through COVID 19 infection once or twice and 75 % of the patients over 65 years of age were vaccinated.

Results:
What were the main clinical findings:

Conclusions:
COVID 19 as a vascular disease and the post- COVID syndrome created a big challenge for the outpatient cardiological practice. The real consequences of this infection are not clear and will be assessed in the future. All the patients who had recovered from COVID 19 have to be followed up at least once in the first year after the infection.
HYPERTENSIVE EMERGENCIES AND BLOOD PRESSURE CONTROL DURING THE COVID-19 PANDEMIC
Authors: Solé Ricardo Cabrera , Turpin Caridad , Luepke Erik , Aguilera Manuel 
Published: June 2023

Objective:
To assess the quality of adequate control of hypertension, during the pandemic and in the year after it in 100 previously treated patients as well as the percentage of hypertensive emergencies (HE).

Design and method:
From July 2020 to July 2021, we studied 100 patients with hypertension, 60 women and 40 men with an age of 72±8 years, who have previously been diagnosed and treated for hypertension. In the first consultation after the pandemic and at 6 months, they underwent an AMPA and a study with home control to all of them. Subsequently, they were asked at 12 months to perform a new home control. The following parameters were measured: systolic and diastolic blood pressure (TAS, TAD), treatment completion (Ctto), control by family doctor (Cmap), the number of times they have gone to the emergency room for uncontrolled tension. Results between the first measurement and 6 months later were compared.

Results:
The BP per home control at baseline was 148±6/98±4 compared at 6 months was 135±2/84±3 (p<0.05). The baseline ABPM: 152±4/89±3 and at 6 months were 135±2/79±3 (p<0.05). The completion was assessed using the Morisky-Green method and basally we found that 45% of patients were compliant, while, at one year it was 100% (at 6 months of the study 68%). Regarding the number of patients who were controlled by their MAP in these first months was only 5% while at the end of the study they were 55% (80% telephone). Of these P, 18 have gone to the emergency room for an HE (18%).

Conclusions:
IMPACT OF THE COVID-19 PANDEMIC ON THE TREATMENT AND ADHERENCE OF HYPERTENSIVE PATIENTS: CHALLENGES AND OUTCOMES
Authors: Pleava Roxana , Vinkele Ilze , Mosteoru Svetlana , Gaita Laura 
Published: June 2023

Objective:
The COVID19 pandemic has seen an important decrease in outpatient clinic visits across all medical specialties as well as a raise in emergency presentations often more severe than previously. Although Sweden has not undergone a strict lockdown, patients’ behaviour was similar to the rest of the European countries. The aim of our study was to evaluate the impact of the pandemic on hypertensive patients follow-up and adherence to medical treatment at a Primary Health Care Center (PHCC) in Sweden.

Design and method:
We conducted a prospective, single centre study which included patients diagnosed with arterial hypertension undergoing regular follow-ups at the PHCC. Inclusion criteria were no record of blood pressure (BP) measurement within the last two years from start date (March 2022) and ongoing prescribed medication from the PHCC. A letter with recommendation to book a follow-up was sent to all the patients who met the inclusion criteria. We analysed patient characteristics, laboratory and prescribed medication at baseline (visit 1) and 6 months after the letters were sent (visit 2).

Results:
213 patients were initially evaluated and 102 patients (aged 64.58 ± 9.45; 61 males, 59.8%) diagnosed with hypertension were included in the study. Out of these 73 patients (71.56%) booked a follow-up visit with 26 patients (35.61%) receiving changes in their medication. The mean BMI between visit 1 and 2 was 30.19 kg/m2 vs. 29.72 kg/m2, p = 0.578. Also there were no significant differences regarding systolic (139.04 ± 13.87 vs. 141.92 ± 14.55, p = 0.103) and diastolic (83.18 ± 9.19 vs. 84.61 ± 8.07, p = 0.176) BP. Most patients were treated with a calcium channel blocker (58 pat, 56.7%) followed by an angiotensin receptor blocker (38 pat, 37.3%). No significant differences were found for the lipidic profile between visits with only 30 patients (29.41%) being on statin at visit 1 compared to 36 patients (35.3%) at visit 2.

Conclusions:
Although patient follow-up was affected by the Covid-19 pandemic, we did not find statistically significant changes in their BP, lipidic profile or weight.
CLINICAL CONSEQUENCES IN POST COVID-19 HYPERTENSIVE PATIENTS
Authors: Matova Olena , Mishchenko Larysa , Talaeva Tatyana , Bezrodnyj Volodymyr , Bozhenko Galina 
Published: June 2023

Objective:
to evaluate the clinical consequences in hypertensive patients after 1.2 ± 0.3 years after COVID-19 recovery.

Design and method:
We studied 51 treated hypertensive patients, which were divided into 2 groups: 26 patients recovered from mild to moderate COVID-19 in 2020-2021 years (1st group) and 25 patients were not ill COVID-19 (2nd group). The clinical characteristics, laboratory finding, echocardiographic measurement and clinical outcomes were analyzed.

Results:
There were no significant differences in sex, age, duration of hypertension, frequency of family history of premature CVD and presence of concomitant obesity, DM, CAD, stroke/TIA, atrial fibrillation, heart failure, CKD, PAD and average number of antihypertensive drugs, office systolic BP between the 2 groups. Levels of office diastolic BP by 10 % (P = 0.001) and heart rate by 13 % (P = 0.01) were higher in post COVID-19 group. Low adherence was present at 81.8 % patients 1st group compared with 45 % of 2nd patients group (P = 0.03). Cognitive impairment by the MMSE scale was detected in 68.2 % of COVID-19 recovered patients and 25 % of 2nd patients group (P = 0.03). Fasting glucose by 7.5 % (P = 0.046), 24-h albuminuria in 1.8 times (P = 0.049), level of CRP by 38.5 % (P = 0.04) were higher and blood concentration of endothelial progenitor cells (CD133+CD31+CD45-/+) by 14, 9 % (P = 0.04), left ventricular ejection fraction by 10 % (P = 0.03) were lower in post COVID-19 patients than in patients of 2nd group.

Conclusions:
The study indicate that the changes were found in the hypertensive patients after 1.2 ± 0.3 years of recovery from COVID-19. In the future these may signal an increased risk for incidence of CV outcomes. Cognitive dysfunction and possibly as a consequence poor adherence to antihypertensive treatment contribute to negative outcomes.